Related Experiment Video
Updated: Sep 5, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.6K
Improving implementation of evidence-based therapies for heart failure
Adam D DeVore1,2, Hayden B Bosworth3,4,5,6,7, Bradi B Granger1,7
1Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Clinical Cardiology
|July 5, 2022
Summary
Evidence-based heart failure treatments improve quality of life and reduce mortality, but their use in routine practice is low. Addressing this implementation gap is crucial for public health and patient outcomes.
Area of Science:
- Cardiology
- Public Health
- Health Services Research
Background:
- Heart failure treatment options have advanced significantly.
- Clinical trials show medical and device therapies improve patient outcomes.
- Suboptimal implementation of these evidence-based therapies is a concern.
Purpose of the Study:
- To identify reasons for the gap between clinical trial results and routine practice for heart failure therapies.
- To review interventions aimed at improving the implementation of evidence-based heart failure care.
- To provide recommendations for future research and clinical practice.
Main Methods:
- Literature review of studies on heart failure therapy implementation.
- Analysis of factors contributing to the evidence-practice gap.
- Synthesis of recommendations for improving care delivery.
Main Results:
- Significant gap exists between evidence-based heart failure therapies and their use in real-world settings.
- Multiple barriers hinder the adoption of effective treatments.
- Recent studies show promise in addressing implementation challenges.
Conclusions:
- Closing the implementation gap in heart failure care is a critical public health priority.
- Targeted interventions are needed to improve guideline-adherent therapy use.
- Future research should focus on scalable and sustainable implementation strategies.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:30Heart Failure VII: Nursing Interventions
134
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
134
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
503
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
503
01:29Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
01:22Heart Failure Drugs: β-Blockers
430
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
430